Princeton OKs Bexsero vaccination campaign; Mylan recalls 480K bottles of blood-pressure med;

@FiercePharma: Monday's most-read story: Takeda's new outsider CFO charged with $1B cost-cutting plan. More | Follow @FiercePharma

@EricPFierce: Patheon, DSM join forces in $2.6B deal, to create no name company with global reach. More | Follow @EricPFierce

@CarlyHFierce: U.S. approves drug tracking, compound pharmacy oversight law. Story from FiercePharmaManufacturing | Follow @CarlyHFierce

> Princeton University decided to offer Novartis' ($NVS) meningitis B vaccination Bexsero to students to help quell a campus outbreak; approved in Europe and Australia, Bexsero will be imported to the U.S. under special rules for products not yet generally cleared by the FDA. Report

> Generics maker Mylan ($MYL) recalled more than 480,000 bottles of its blood pressure medication amlodipine besylate because their active ingredient didn't meet manufacturing standards. Report

> Teva Pharmaceutical Industries ($TEVA) launched two branded drugs for cancer patients, Lonquex and Granix, in Germany and the U.S., respectively. Report

> Gilead Sciences ($GILD) won European approval for its HIV drug Vitekta after the FDA refused to clear it for sale in April. Report (sub. req.)

> Merck ($MRK) said it would bring its campaign to reduce pregnancy-related deaths, now active in Africa, to the U.S., where rates have sharply increased. Report

> Medicare's failure to track doctors' prescribing habits wastes billions on unnecessary brand-name drugs, a study found. Report

> Teva teamed up with an Australian supplements company, via its joint venture with Procter & Gamble ($PG), to expand its range of products globally. Report

Medical Device News

@FierceMedDev: Study: Medtronic next-gen pacer tech achieves atrial fibrillation delay. More | Follow @FierceMedDev

@MarkHFierce: Cardiovascular Systems wants to sell 2.1M shares in a public offering. Simply put: expansion requires funding. Story | Follow @MarkHFierce

@MichaelGFierce: Spoke to MIT's Dr. Robert Langer about drug delivery and nanotech. Story in tomorrow's FierceDrugDelivery report. | Follow @MichaelGFierce

> Congress faces pushback over proposed Medicare medical imaging cuts. Item

> Medtronic's otherwise stellar Q2 stained by spinal revenue declines. More

> NEJM: Stents don't beat drugs in treating clogged renal arteries. Article

Biotech News

@FierceBiotech: Gilead charts PhIII success for leukemia drug as J&J showdown awaits. More | Follow @FierceBiotech

@JohnCFierce: Check out my webinar Thursday morning with Toni Ribas and Carol Gallagher on targeted cancer drugs. More | Follow @JohnCFierce

@DamianFierce: AstraZeneca just can't wait to get to Cambridge, plans to deploy 400 scientists to get R&D ball rolling. Story | Follow @DamianFierce

@EmilyMFierce: As resistance rises, one MIT team is investigating how a bacteria-derived toxin could help design new antibiotics. Article | Follow @EmilyMFierce

> Merck spotlights promising data on 'breakthrough' cancer immunotherapy MK-3475. More

> Amgen's cancer-fighting virus boosts melanoma survival in PhIII study. Article

Pharma Manufacturing News

> Glaxo to use new technology in India plant. Report

> 2 Puerto Rico plants up next in Merck job-whacking plan. Story

> J&J, Merck KGaA roll out new China plant projects. Article

> DSM, Patheon join up in $2.6B deal. More

> U.S. approves drug tracking, compound pharmacy oversight law. Story

> Mylan recalls 480,000 bottles of blood pressure med. Item

Biotech Research News

> Tekmira's RNAi antivirals protect animals from lethal doses of Ebola, Marburg. More

> Oxford, MRC Technology team up on migraine drug discovery. Item

> First-ever 'mini-kidney' organs created from human stem cells. Story

> Bacteria-derived toxin could provide design for new antibiotics. Article

> Herb-based compounds improve learning, memory in Alzheimer's mice. News

> Compound that targets fat-burning mechanism discovered. Report

And Finally... AstraZeneca ($AZN) selected the architecture firm Herzog & de Meuron to design its new hub and headquarters in Cambridge, U.K. Report